All News
Our old friend, hydroxychloroquine
After an action packed weekend, RheumNow Live 2023 concluded on Sunday with a half-day session on systemic lupus erythematous and ankylosing spondylitis discussing many new medications that are revolutionizing rheumatology. Dr. Laurent Arnaud, a professor at Strasbourg University in France, however, took the time to review one of our oldest therapies: hydroxychloroquine.
Read Article
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush RheumNow ( View Tweet)
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB
Links:
Dr. John Cush RheumNow ( View Tweet)
LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication.
🧵1of2 https://t.co/VZL9qJu9kF
Lupus Research LupusResearch ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush RheumNow ( View Tweet)
The AURORA study with voclosporin has changed the way that Dr. Kalunian practices. He now uses lower doses of steroid, 40mg in induction with a faster taper in lupus nephritis. #RNL2023 @RheumNow https://t.co/8ss14Z5WXl
Dr. Rachel Tate uptoTate ( View Tweet)
Reassuring data by Dr. Laurent Arnaud on HCQ
- arrhythmia risk from HCQ similar to general population
@RheumNow #RNL2023 https://t.co/vMDg2SlbJQ
Robert B Chao, MD doctorRBC ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/MwruMhmvPq https://t.co/WnCvCZtq6z
Links:
Dr. John Cush RheumNow ( View Tweet)
BEAT LUPUS trial results showed that belimumab after RTX reduced dsDNA levels/flaring. Questions remain if this can be a successful combination in lupus nephritis. Dr. Kalunian #RNL2023 @RheumNow https://t.co/XeuybrWigf
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate uptoTate ( View Tweet)
How does HCQ work
@Lupusreference in #RNL2023
HCQ works by inhibition of Toll-like receptor (TLR) with affects on IFN
HCQ works as base to increase lysosomal pH and affect cellular function
@RheumNow https://t.co/RTEUF0cS0u
Eric Dein ericdeinmd ( View Tweet)
@Lupusreference in #RNL2023
HCQ and arrhythmia via QTc prolongation
At normal doses, same as general population
If on other QTc prolonging medications, a baseline EKG may be beneficial
@RheumNow https://t.co/cAN2vBNa1t
Eric Dein ericdeinmd ( View Tweet)
Any dose more than 1500 is associated with retinopathy ? So what to do. @Lupusreference #RNL2023 @RheumNow https://t.co/2zdjpcuvKa
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Smoking and SLE
Smoking increases SLE activity
Smoking decreases HCQ efficacy
Skin response on HCQ down 50% in smokers 🚬
@Lupusreference #RNL2023 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
TULIP trials in lupus, disease outcomes and others, by Richard Furie #RNL2023 @RheumNow https://t.co/uUQOxUIzJN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Furie: #RNL2023
Anifrolumab - anti type 1 IFN receptor- blocks all 5 IFN, 90% IFN gene signature decrease
Improved from prior older failed medication sifalimumab which only blocked IFNalpha- only 25% interferon gene signature
@RheumNow https://t.co/30oFRwwuTG
Eric Dein ericdeinmd ( View Tweet)
✅ Check my TAKE-HOME MESSAGES about #hydroxychloroquine & #Lupus for RheumNow Live 2023 #RNL2023
@RheumNow ⬇️ https://t.co/E2xdv3ODG6
Laurent ARNAUD Lupusreference ( View Tweet)
SRI Responders more likely able to reduce prednisone and far
Serological improvement
SF-36
Fatigue
by Richard Furie #RNL2023 @RheumNow https://t.co/ilsyOXw7nA
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Compliance is always an issue, by Richard Furie #RNL2023 @RheumNow .
Plaquenil level were below target. Adherence is always something we need to work on. https://t.co/hMgL9kY0rZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
